This document discusses cervical carcinoma, including its definition, epidemiology, risk factors, screening and prevention methods, diagnosis, staging, and treatment. It notes that cervical cancer is the 4th most common cancer in women worldwide, with over 80% of cases occurring in developing countries. Screening methods discussed include the Pap smear, HPV testing, and visual inspection with acetic acid. Treatment depends on the stage of cancer, and may include surgery such as hysterectomy or cone biopsy, radiation therapy, or chemoradiation for more advanced stages. The document provides details on the FIGO staging system and comparisons between the 2018 and 2009 versions.
Welcoming remarks by Dr Osborne E Nyandiva on Symposium: Cervical cancer and its prevention
Co-Presenter Dr Giama. We are happy to present to you this very crucial discussion on Cancer.
Cervical cancer is a type of cancer that develops in a woman's cervix (the entrance to the womb from the vagina).
Cancer of the cervix often has no symptoms in its early stages. If you do have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause.
Welcoming remarks by Dr Osborne E Nyandiva on Symposium: Cervical cancer and its prevention
Co-Presenter Dr Giama. We are happy to present to you this very crucial discussion on Cancer.
Cervical cancer is a type of cancer that develops in a woman's cervix (the entrance to the womb from the vagina).
Cancer of the cervix often has no symptoms in its early stages. If you do have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause.
this lecture for undergraduates, GP & gynecologists
it includes full simple explanation of CIN (cervical intraepithelial neoplasia)
how to do screening for cervical cancer
methods of screening that include pap smear and HPV testing
it also includes the diagnostic method for the cervical cancer by taking biopsy directed by colposcopy
colposcopy and its rule
how to deal with CIN different grades
follow up after CIN treatment
Gain a deeper understanding of uterine and endometrial cancer symptoms, diagnosis, treatment options, and current research trends with Dr. Jason D. Wright, Division Chief of Gynecologic Oncology at New York-Presbyterian/Columbia University Medical Center. This webinar is a collaboration with the Foundation for Women's Cancer.
The Cervical Cancer is the second most common cancers and it can be easily prevented by timely screening & proper education, awareness program for women.
Say no to cervical cancer-PUBLIC Awareness-Life Care Centre_Dr.Sharda JainLifecare Centre
Ā
Cervical Cancer in INDIA
Say no to cervical cancer
Dr.Sharda Jain
Life Care Centre
PUBLIC Awareness_Dr.Sharda Jain
HPV Infection
HPV Vaccination
Cervical Screening
SEE & TREAT Programme tp Prevent Cervical Cancer
this lecture for undergraduates, GP & gynecologists
it includes full simple explanation of CIN (cervical intraepithelial neoplasia)
how to do screening for cervical cancer
methods of screening that include pap smear and HPV testing
it also includes the diagnostic method for the cervical cancer by taking biopsy directed by colposcopy
colposcopy and its rule
how to deal with CIN different grades
follow up after CIN treatment
Gain a deeper understanding of uterine and endometrial cancer symptoms, diagnosis, treatment options, and current research trends with Dr. Jason D. Wright, Division Chief of Gynecologic Oncology at New York-Presbyterian/Columbia University Medical Center. This webinar is a collaboration with the Foundation for Women's Cancer.
The Cervical Cancer is the second most common cancers and it can be easily prevented by timely screening & proper education, awareness program for women.
Say no to cervical cancer-PUBLIC Awareness-Life Care Centre_Dr.Sharda JainLifecare Centre
Ā
Cervical Cancer in INDIA
Say no to cervical cancer
Dr.Sharda Jain
Life Care Centre
PUBLIC Awareness_Dr.Sharda Jain
HPV Infection
HPV Vaccination
Cervical Screening
SEE & TREAT Programme tp Prevent Cervical Cancer
Surgical Management of Cervical Cancer 11052023 FOGSI PAC LECTURE WEBINAR.pptxNiranjan Chavan
Ā
Cancer of the uterine cervix is the third most common gynecologic cancer diagnosis and cause of death among gynecologic cancers. Cervical cancer has lower incidence and mortality rates than uterine corpus and ovarian cancer, as well as many other cancer sites. However, in countries that do not have access to cervical cancer screening and prevention programs, cervical cancer remains a significant cause of cancer morbidity and mortality. This PPT intends to teach about surgical management of Ca Cervix.
A brief discussion over CA Cervix. All newest updates in management protocol and revised by reknowned gynecologistts. Very much helpful for both under and post graduate students/Doctors.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
Ā
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Ā
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Global launch of the Healthy Ageing and Prevention Index 2nd wave ā alongside...ILC- UK
Ā
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
How many patients does case series should have In comparison to case reports.pdfpubrica101
Ā
Pubricaās team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
Ā
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
2. Definition
ā¢ It is the malignant neoplasm of the cervix.
ā¢ May arise from :
ā¢ The surface epithelium of the cervix
)exocervical c 85%)
ā¢ From the epithelial lining of the
cervical canal (endocervical carcinoma 15 %).
5. Cervical Cancer Worldwide
230,000 women die
of cervical cancer
every year
ā 80 % occur in
developing
countries.
āWHO , Cervical Cancer Screening in Developing
Countries. Report of a WHO Consultation. 2001ā
6. Incidence of Cancers in
Egyptian Women
0
5
10
15
20
25
Breast
Cancer
Cervical
Cancer
Ovarian
Cancer
Uterine
Cancer
Percent
Source: GLOBOCAN 2000.
7. Who is at risk?
Exo cx carcinoma :
Women who have had more than one partner
Women whoās partner (s) has had more than one
sexual partner.
Women with STI
8. Who is at risk?
Women with immune problems:
ā Steroid medications
ā Transplanted organs
ā Chemotherapy
ā HIV
Women who smoke
1st intercourse before Age 18
Endocervical c
( like Endometrial cā¦Obesity , Diabetes , hypertension , low parity , endometrial hyperplasia)
9. STI
All over the world; HPV 16,18
are present in most cases.
In Mansoura study ,it was
found only in 45% of cases.
10. Screening & Prevention
1. Prevention is better than cure.
2. Most Cancers Develop In The Unscreened
And The Under screened populations
11. Serious
Widespread
Diagnosable in early stages.
Treatable
Cancer cx. Screening programs are in
adulthood.
But ov. cancer programs are still in relative
infancy, why?
Cancer Cervix Is an Ideal DiseaseFor
Screening
12. Gold standard Screening
test For Cancer Cervix
ā¼ PAP smear test is
considered to be the
gold standard .
ā¼ Has limitations ?
17. Cervical intraepithelial neoplasia (CIN)
Transformation of cervical epithelium witch may
regress or progress to invasive cancer over >10 years.
CIN 1ā¦ā¦ā¦.lower 1/3
CIN 2ā¦ā¦ā¦lower 2/3
CIN 3ā¦ā¦ā¦ā¦..All epithelium except superficial cells
CISā¦ā¦ā¦ā¦ā¦ā¦All epithelium replaced by
malignant cells.
18. Bethesda system depends on
cytological criteria
Normal.
-Atypical squamous cells of undetermined significance (ASCUS)
-LGSILā¦ā¦ā¦ā¦ā¦CIN 1
-HGSILā¦ā¦ā¦..CIN2, CIN3, CIS
25. Alternatives to Pap smear
ā Automated pap screening.
ā Visual inspection with acetic acid
(VIA), with magnification (VIAM)
&iodine (VILI).
ā HPV testing.
ā Polar probe.
ā cervicography
26. HPV testing
Detect High Risk HPV.
Sample from cervix-
similar to PAP.
Special transport
medium
Processed in the lab
Objective tests
Not suitable for Egypt))
Expensive
28. Via Is An Ideal Alternative to Pap smear
Keep a bottle
of vinegar in
your office.
29. inexpensive&1. Simple & quick
2. Immediate results
3. Not need cytopathologist .
4. One step diagnosis and ttt.
5. Sensitive
6. Specific??????
Advantages of VIA over PAP
30. WHO 2013 & VIA
ļÆ VIA ā¦.should be an integral
step of inspection of cervix ā
uteri on routine pelvic
examination in low resource
countries.
ļÆ As recommended by WHO project for the developing
countries 2013 (field studies in India & South Africa).
39. Diagnosis: 1- History.
ā¢
ā¢
ā¢
ā¢
ā¢
ā¢
ā¢
ā¢
Many women are a symptomatic .
Presented with abnormal routine cx smear
Complain of abnormal vaginal bleeding
I M bleeding
post coital bleeding
perimenopausal bleeding
postmenopausal bleeding
blood stain vaginal discharge
40. Diagnosis : 1) History
-Increased vaginal discharge
-Pelvic pain
-Pain during sex ( Dyspareunia)
-Foul smelling discharge
41. 2- Examination:
ā¢ PV exam using cuscuās speculem
ā¢ Nothing is found in early stage .
ā¢ Mass ,ulcerating fungating
ā¢ P/V& P/R is very helpful.
44. Patterns of spread
cervical stroma, vagina, andā¢ Direct invasion
parametrium.
ā¢ Lymphatic spread pelvic and then par aortic
lymph nodes
ā¢ Hematogenous spread such as lungs, liver, and
bone
45. Lymphatic Spread
ā Primary Group
ā
ā
ā
ā
ā
ā Parametrial nodes
Paracervical/ureteral nodes
Obturator nodes
Hypogastric nodes
External iliac nodes
Sacral nodes
ā Secondary Group
ā
i
ā
ā Common Iliac nodes
Inguinal nodes (deep and s
Periaortic nodes
47. Rationale Of staging
ā¢ Staging is clinical
ā¢ FIGO staging
ā¢ Based on EUA, cystoscopy +/-
sigmoidoscopy
ā¢ Does NOT include MRI
48. CervicalCancer
ā¢ Stage I: The carcinoma is confined strictly to the cervix
ā¢ Stage II: The tumor extends to the upper part of the vagina. It may
extend beyond the cervix into nearby tissues toward the
pelvic wall with depth between 5-7mm. The tumor does not
invade the lower third of the vagina or the pelvic wall.
ā¢ Stage III: The tumor extends to the lower part of the vagina.
It may also have invaded the pelvic wall.
If the tumor blocks the flow of urine, one or both kidneys
may not be working well.
ā¢ Stage IV: The tumor extend beyond the true pelvic or has involved the
mucosa of the bladder or rectum or spread to other parts of
the body.
ā¢ Recurrent
cancer:
The cancer was treated, but has returned after a period of
time during which it could not be detected. The cancer may
show up again in the cervix or in other parts of the body.
Staging
49. The tumor extends to the pelvic wall and/or involves lower third of the vagina and or causes hydronephrosis or non-functioning kidney**
Stage IIIA: Tumor involves lower third of the vagina, with no extension to the pelvic wall
Stage IIIB: Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney
The carcinoma is strictly confined to the cervix
(extension to the corpus would be disregarded)
Stage IA: Invasive carcinoma which can be diagnosed only by microscopy, with deepest invasion ā¤5 mm and largest extension ā¤7 mm
Stage IA1: Measured stromal invasion of ā¤3.0 mm in depth and extension of ā¤7.0 mm.
Stage IA2: Measured stromal invasion of >3.0 mm and ā¤5.0 mm with an extension of not >7.0 mm
Stage IB: Clinically visible lesions limited to the cervix uteri or pre-clinical cancers greater than stage IA*
Stage IB1: Clinically visible lesion ā¤4.0 cm in greatest dimension
Stage IB2: Clinically visible lesion >4.0 cm in greatest dimension
The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum.
A bullous edema, as such, does not permit a case to be allotted to Stage IV
Stage IVA: Spread of the growth to adjacent organs.
Stage IVB: Spread to distant organs.
Stage II
Stage I
FIGO staging system, 2009
Cevical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina
Stage IIA: Without parametrial invasion
Stage IIA1: Clinically visible lesion ā¤4.0 cm in greatest dimension
Stage IIA2: Clinically visible lesion >4 cm in greatest dimension
Stage IIB: With obvious parametrial invasion
Stage III
Stage IV
*All macroscopically visible lesionsāeven with superficial invasionāare allotted to stage IB carcinomas. Invasion is limited to a measured stromal invasion with a maximal depth of 5.00 mm and a horizontal
extension of not >7.00 mm. Depth of invasion should not be >5.00 mm taken from the base of the epithelium of the original tissueāsuperficial or glandular. The depth of invasion should always be reported
in mm, even in those cases with āearly (minimal) stromal invasionā (~1 mm). The involvement of vascular/lymphatic spaces should not change the stage allotment.
** On rectal examination, there is no cancer-free space between the tumor and the pelvic wall. All cases with hydronephrosis or non-functioning kidney are included, unless they are known to be due to
another cause.
50. FIGO 2018 specification
ļIncorporates importance of modern imaging findings
ļIncorporates microscopic finding in early cervix
limited disease .
ļAbolishes importance of horizonal spread in
microscopic disease
ļSpecific stage group has been assigned to lymphnode
positive patients
51. Stage Description 2018 Description 2009
I
Confined to cervix only, disregarding uterine corpus
involvement
Confined to cervix only, disregarding uterine
corpus involvement
IA
Invasive carcinoma, diagnosed only by microscopy,
with maximum depth of invasion <5 mm
Invasive carcinoma, diagnosed only by
microscopy. Maximum depth of stromal
invasion 5mm, maximum horizontal spread
7mm
IA1
Stromal invasion <3 mm in depth Stromal invasion ā¤3 mm in depth, horizontal
spread ā¤7mm
IA2
Stromal invasion ā„3 mm and <5 mm in depth Stromal invasion >3 ā¤5 mm
in depth, horizontal
spread ā¤7mm
IB
Stromal invasion ā„5 mm (greater than Stage IA)
but limited to the cervix uteri
Clinically visible lesion confined to cervix or
lesion > IA2 including superficial lesions
IB1
Stromal invasion ā„5 mm and tumor <2 cm in
greatest dimension
Clinically visible lesion, ā¤ 4cm
in greatest dimension
IB2
Invasive carcinoma ā„2 cm and <4 cm in greatest
dimension
Clinically visible lesion, > 4cm
in greatest dimension
IB3 Invasive carcinoma ā„4 cm in greatest dimension
dodulmondal@gmail.com
NONE
52. Stage Description 2018 Description 2009
II Carcinoma invades beyond the uterus but
not extending onto the lower third of the
vagina or to the pelvic wall
Carcinoma invades beyond the uterus
but not extending onto the lower third
of the vagina or to the pelvic wall
IIA Tumor extending beyond uterus but not
involving lower third of vagina and without
parametrial invasion
Tumor extending beyond uterus but not
involving lower third of vagina and
without parametrial invasion
IIA1 Invasive carcinoma <4 cm in greatest
dimension
Clinically visible, ā¤ 4cm
in greatest
dimension
IIA2 Invasive carcinoma ā„4 cm in
greatest dimension
Clinically visible tumor, >4cm
in greatest
dimension
IIB With parametrial involvement but not up
to the pelvic wall
With parametrial involvement but not up
to the pelvic wall
dodulmondal@gmail.com
53. Stage Description 2018 Description 2009
III Carcinoma involves lower third of vagina and/or
extends to pelvic wall and/or causes hydronephrosis
or nonfunctoning kidney and/or involves pelvic
and/or para-aortc lymph nodes
Carcinoma extending to lateral pelvic wall and/or
involving the lower third of vagina and/or causing
hydronephrosis or nonfunctioning kidney
IIIA The carcinoma involves the lower third of the
vagina, with no extension to the pelvic wall
The carcinoma involves the lower third of
the
vagina, with no extension to the pelvic wall
IIIB Extension to the pelvic wall and/or
hydronephrosis or nonfunctoning kidney
(unless known to be due to another cause)
Extension to the pelvic wall and/or
hydronephrosis or nonfunctoning kidney
(unless known to be due to another cause)
IIIC Pelvic and or para-aortic lymphadenopathy
irrespective of tumor size and extent. r or p used
to denote radiological or pathological
involvement NONE
IIIC1 Pelvic LN only
IIIC2 Para aortic (Ā± Pelvic LN)
dodulmondal@gmail.com
54. Stage Description 2018 Description 2009
IV
The carcinoma has extended beyond the true
pelvis or has involved (biopsy proven) the
mucosa of the bladder or rectum. (A bullous
edema, as such, does not permit a case to be
alloted to Stage IV) or spread to distant
organs
The carcinoma has extended
beyond the true pelvis or has
involved (biopsy proven) the
mucosa of the bladder or
rectum. (A bullous
edema, as such, does not permit a case to
be alloted to Stage IV) or spread to
distant organs
IVA
Spread to adjacent pelvic organs
Invading bladder or rectal mucosa (biopsy
proven). Bullous edema alone disregarded
IVB
Spread to distant organs Distant organ metastasis
dodulmondal@gmail.com
57. Factors For choice of treatment
ā¢ Patient
ā¢ Fitness of the patients
ā¢ Age of the patients
ā¢ Disease:
ā¢ Stage
ā¢ Type of lesion
ā¢ Gynecologist:
ā¢ Experience
ā¢ The resources available.
61. Werthemeimās hystrectomy
ā¢ Total abdominal hystrectomy including:
ā¢ the parametrium.
ā¢ Pelvic lymphadenectomy
ā¢ 3 cm vaginal cuff
ā¢ The original operation conserved the ovaries
,since squamouss cell carcinoma does not
spread dirctly to the ovaries.
ā¢ Oophorectomy should be performed in cases of
adenocarcinoma as there is 5-10% of ovarian
metastosis
62. complications
ā¢ Low blood counts
ā¢ Uteric pain due to
pyelitis and
pyelonephritis
ā¢ Vesicovaginal fistula
ā¢ Menorrhagia
ā¢ Post-menopausal PV
bleed
Disease related Related to surgery
ā¢ Infection & sepsis
ā¢ Hemorrhage
ā¢ Severe pain
ā¢ Shock
63. Complications (cont..)
Related to radiation
ā¢
ā¢ Anorexia
ā¢ Fatigue.
ā¢ Nausea .
ā¢ Vomiting
ā¢ Skin changes, which range from
redness (like a sunburn) to
ā¢ blistering and peeling where
the radiation enters the body
Low blood counts
Related to chemotherapy
ā¢ Immune suppression
ā¢ Myeolosupression
ā¢ mucositis
ā¢ Nausea
ā¢ Vomiting
ā¢ Diarrhea
ā¢ Alopecia
ā¢ Loss of appetite
ā¢ Increased chance of infection
ā¢ Easy bruising or bleeding
ā¢ Fatigue
65. prognosis
ā¢ Depends on clinical stage
ā¢ Pathologocal type Adenocarcinoma and
adenosquamous carcinoma have a
somewhat lower 5-year survival rate
than squamous carcinoma, stage for
stage